Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

MET

6 articles · Resources: NCBI Gene, OncoKB

Clinical

Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma

Busse C, Hörner M, Saravi B, et al.

Oral and maxillofacial surgery

This retrospective study investigated the spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma (OSCC) by comparing primary tumors and matched lymph node metastases. Findings revealed that both PD-L1 and c-MET were frequently expressed in primary tumors but at significantly lower levels in corresponding lymph node metastases. A substantial discordance in PD-L1 CPS status was observed between the two tumor compartments, potentially impacting biomarker classification. While higher PD-L1 expression in primary tumors was associated with nodal metastasis, no significant correlation was found between PD-L1 and c-MET. These results highlight the critical role of spatial heterogeneity in biomarker assessment for OSCC.

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical · Molecular biology · Bioinfo & AI

Artificial intelligence-based diagnostic model for identifying PTPRZ1-MET fusion in a clinically defined secondary glioblastoma cohort

Zhang JH, Shi J, Zhou HX, et al.

Molecular biomedicine

This study analyzed 159 patients with secondary glioblastoma (sGBM) and confirmed that the PTPRZ1-MET fusion is a recurrent oncogenic driver associated with significantly shorter overall and progression-free survival. Researchers identified 359 upregulated genes in fusion-positive tumors, enriched in cell-cycle regulation pathways. An artificial intelligence-based diagnostic model, utilizing a three-gene panel (MET, PCDHGA3, FAM3C), was developed and validated to identify this fusion. This robust molecular signature could facilitate the identification and stratification of sGBM patients positive for the PTPRZ1-MET fusion.

Clinical · Molecular biology · Bioinfo & AI

MET-amplified gastric cancers exhibit co-amplifications of BRAF, CDK6, and EGFR

Lüschen S, Ebert U, Behrens HM, et al.

The journal of pathology. Clinical research

This study investigated additional genetic alterations in MET-amplified gastric cancers (GCs), which are associated with poor prognosis and limited response to targeted therapies. Researchers found that MET amplification is frequently accompanied by co-amplifications of other oncogenes located on chromosome 7, such as BRAF, CDK6, and EGFR, in 54% of cases. These co-amplifications exhibit significant intra- and intertumoral heterogeneity. This complex heterogeneity may explain the diagnostic and therapeutic challenges, subclonal evolution, and the failure of targeted therapies in MET-amplified GCs.

Clinical · Molecular biology

Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

Dymun A, Jeng MY, Elkrief A, et al.

Science translational medicine

This study investigates histologic transformation to lung squamous cell carcinoma (LUSC) in EGFR-mutant lung adenocarcinoma (LUAD) patients, an underrecognized resistance mechanism. Multiomic analyses revealed that patients with transforming or adenosquamous (LUAS) phenotypes experienced shorter overall survival on first-line osimertinib. Inactivation of the retinoblastoma (Rb) pathway, particularly via CDKN2A/B deletions, was identified as a key driver of this transformation. Furthermore, MET pathway upregulation was observed, and combined EGFR and MET inhibition demonstrated efficacy in preclinical models. These findings suggest novel strategies to counteract this aggressive form of resistance.

Clinical · Molecular biology

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib

Piotrowska Z, Ahn MJ, Voon PJ, et al.

Cancer discovery

The prospective, multicenter ELIOS study characterized acquired resistance mechanisms to first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). By analyzing paired tumor biopsies taken pre-treatment and post-progression, the study identified frequent alterations including MET amplification, CDKN2A/CDKN2B and MTAP deletions, and the EGFR C797S mutation. Proteogenomic analysis also revealed high TROP2 expression, irrespective of genetic alterations. The findings highlight the heterogeneous nature of resistance and the complementary utility of tissue and liquid biopsies for alteration detection. This study emphasizes the need for therapeutic strategies targeting multiple resistance pathways.